Study of a port and catheter system for spinal muscular atrophy
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This study tests a new device called the ThecaFlex DRx System, which is a small port and catheter placed under the skin to deliver Spinraza directly into spinal fluid—instead of needing repeated spinal taps. The device aims to make receiving medication easier and safer for people with SMA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 3 years old.
- You have spinal muscular atrophy (SMA) and need treatment with Spinraza.
- Spinal taps (lumbar punctures) are hard for you—either because of breathing problems, other health issues, or your doctor believes a special catheter would help.
- You can have surgery to put the port and catheter under your skin.
- You agree to complete all study visits and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
This study tracks how well the gene therapy ITVISMA works in everyday medical practice for people with spinal muscular atrophy (SMA). It aims to see if the treatment is safe and effective in a real-world setting.
This study looks at how muscles work in children and young adults with spinal muscular atrophy (SMA) who are taking or starting SMN-directed therapies (like Evrysdi, Spinraza, or Zolgensma). It aims to understand the body's response to these treatments, which could help improve future care.
This trial tests a medicine called salanersen (BIIB115) to see how well it improves movement and how safe it is in people with spinal muscular atrophy (SMA). It includes those who have never taken an SMA drug or are currently on risdiplam and willing to switch.
This early-stage study tests whether a one-time gene therapy can safely improve outcomes for babies with the most severe type of spinal muscular atrophy (SMA type 1). It focuses on safety and early signs of benefit, and participation requires specific genetic and health criteria.
This trial investigates how the drug nusinersen (Spinraza) enters the body when given through a small, flexible tube placed in the lower back (ThecaFlex DRx system). It aims to learn how the drug is processed in adults and children with spinal muscular atrophy, which could help make dosing more convenient.
Hear when a new Spinal Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.